Pipeline-Protecting Patent Sublicenses
Executive SummaryAn often-overlooked complication on the path from discovery of a novel biotech therapeutic to a commercialized product is patent infringement. In this column, we examine the terms of patent-sublicenses made to protect a product in development or on the market from patent-related lawsuits.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.